Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

R M Hoetelmans; P L Meenhorst; J W Mulder; D M Burger; C H Koks; J H Beijnen

doi:10.1023/a:1008629608556

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

Pharm World Sci. 1997 Aug;19(4):159-75. doi: 10.1023/a:1008629608556.

Authors

R M Hoetelmans¹, P L Meenhorst, J W Mulder, D M Burger, C H Koks, J H Beijnen

Affiliation

¹ Department of Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands.

PMID: 9297727
DOI: 10.1023/a:1008629608556

Abstract

In this review the clinical pharmacology of HIV protease inhibitors, a new class of antiretroviral drugs, is discussed. After considering HIV protease function and structure, the development of inhibitors of HIV protease is presented. Three protease inhibitors are reviewed in more detail: saquinavir, indinavir, and ritonavir. Clinical trial results with these agents are evaluated. Furthermore, adverse effects, resistance, dosage and administration, clinical pharmacokinetics, pharmacokinetic-pharmacodynamic relationships, and drug interactions are discussed.

Publication types

Review

MeSH terms

Acquired Immunodeficiency Syndrome / drug therapy
Clinical Trials as Topic
HIV Protease / genetics
HIV Protease / metabolism
HIV Protease Inhibitors / pharmacokinetics
HIV Protease Inhibitors / pharmacology*
HIV Protease Inhibitors / therapeutic use
Humans
Indinavir / pharmacokinetics
Indinavir / pharmacology
Indinavir / therapeutic use
Ritonavir / pharmacokinetics
Ritonavir / pharmacology
Ritonavir / therapeutic use
Saquinavir / pharmacokinetics
Saquinavir / pharmacology
Saquinavir / therapeutic use

Substances

HIV Protease Inhibitors
Indinavir
HIV Protease
Saquinavir
Ritonavir